Flash update Santhera Valuation Report "Against all odds"

The Catalyst licensing deal for vamorolone rights in North America, valued at up to USD 231 mn plus royalties, significantly improves the risk/reward profile for Santhera avoiding substantial dilution to raise cash for a US sales force, extends the cash runway into Q1 2025 and an experienced partner for North America.

Key catalysts include:

1. Vamorolone US approval in DMD - PDUFA (26 October 2023)
2. Vamorolone EU approval in DMD (Q4 2023)
3. Vamorolone UK approval in DMD (Q4 2023)

Read the full Santhera Valuation Report